To assess the contribution of NF-κB inhibition in glial cells in the pathogenesis of ALS, we have generated two different double transgenic mice lines by crossing SOD1G93A mice with the two independent GFAP-IκBαAA transgenic lines described above, in order to exclude a founder effect. The gene discussed is NFKB1; the disease is amyotrophic lateral sclerosis.